



## **Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA**

January 7, 2020

SAN FRANCISCO, Jan. 7, 2020 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2020 at 2:30 p.m. Pacific Time.

The presentation will be accessible via a Webcast through a link posted on the Investors, Events Calendar section of the Nektar website: <https://ir.nektar.com/events-and-presentations/events>. In addition, the company will webcast the Q&A breakout session immediately following its presentation at 3:00 p.m. Pacific Time. This Webcast will be available for replay until February 21, 2020.

### **About Nektar Therapeutics**

Nektar Therapeutics is a research-based, development-stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, autoimmune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at <http://www.nektar.com>.

### **Contacts:**

#### **For Investors:**

Vivian Wu of Nektar Therapeutics  
628-895-0661

#### **For Media:**

Jodi Sievers of Nektar Therapeutics  
415-482-5593

Dan Budwick of 1AB  
973-271-6085  
[dan@1abmedia.com](mailto:dan@1abmedia.com)

 View original content: <http://www.prnewswire.com/news-releases/nektar-therapeutics-president-and-ceo-howard-robin-to-present-at-the-38th-annual-jp-morgan-healthcare-conference-in-san-francisco-ca-300982385.html>

SOURCE Nektar Therapeutics